Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Is imitation really the highest form of flattery? It appears drug giant Amgen Inc. ( AMGN , Financial) certainly thinks so.

Amgen's Big Bet on Copycat Drugs Is Paying Off

Blackrock Inc

Crown Castle International

Comcast

EOG Resources

Home Depot

Packaging Corp of America

Pinnacle West Capital

Ross Stores

Tyson Foods

Texas Instruments

Union Pacific

I present my top dividend growth stock in each of the 11 GICS Sectors. The 11 stocks are discounted and have safe dividends.

My Top Dividend Growth Pick In Each GICS Sector

Microsoft

2 Stocks That Could Survive the Next Recession

Abbott Labs

Johnson & Johnson

With so much carnage in the stock market right now, investors are rushing to the exits trying to preserve what gains they have left. In a market-wide sell-off, stocks of all stripes get sold off, regardless of quality.

3 Oversold Health Care Stocks Set for a Rebound

Founding and Lead Sponsor in Collaboration with the Vice Provost  of Advances in Learning at Harvard University THOUSAND OAKS, Calif. , June 20, 2022 /PRNewswire/ -- The Amgen Foundation today announced an increased commitment to LabXchange, an online science education platform that provides users with access to high-quality science education resources at no cost.

AMGEN FOUNDATION MORE THAN DOUBLES COMMITMENT TO LABXCHANGE, FREE VIRTUAL SCIENCE EDUCATION PLATFORM

Chevron

Dow Inc

Merck

Travelers

As investors continue monitoring the Federal Reserve's actions to control inflation, five Dow Jones Industrial Average stocks that have outperformed the Standard & Poor's 500 Index in the year to date include Chevron Corp. ( CVX , Financial), Merck & Co. Inc. ( MRK , Financial), The Travelers Companies Inc. ( TRV , Financial), Amgen Inc. ( AMGN , Financial) and Dow Inc. ( DOW , Financial) according to the All-in-One Screener, a Premium feature of GuruFocus.

5 Dow Stocks Outperforming the S&P 500 Year to Date

Amgen Inc. (NASDAQ:AMGN ) Goldman Sachs 43rd Annual Global Healthcare Conference June 15, 2022 4:40 PM ET Company Participants Peter Griffith - Executive Vice President, Chief Financial Officer Dave Reese - Executive Vice President, Research & Development Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good morning. Thanks everyone for joining us, really pleased to have the Amgen team with us.

Amgen Inc. (AMGN) Management Presents at Goldman Sachs 43rd Annual Global Healthcare Conference

Amgen's Lumakras revenue is ramping rapidly. Amgen Phase 2 topline olpasiran data was positive.

Amgen Compelling On New Data And Biosimilar Approval

AbbVie

Bank of America

Intel

Prologis

If this roiling market is making you seasick, then it's an excellent time batten down the hatches with these reliable dividend stocks. The post 7 Dividend Stocks to Buy for Your Grandkids appeared first on InvestorPlace.

7 Dividend Stocks to Buy for Your Grandkids

THOUSAND OAKS, Calif. , June 10, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 43rd Annual Healthcare Conference at 1:40 p.m.

AMGEN ANNOUNCES WEBCAST OF GOLDMAN SACHS 43RD ANNUAL HEALTHCARE CONFERENCE

Amgen Inc. (NASDAQ:AMGN ) 2022 Jefferies Global Healthcare Conference June 8, 2022 9:30 AM ET Company Participants Arvind Sood - Vice President, Investor Relations Murdo Gordon - Executive Vice President, Global Commercial Operations Conference Call Participants Michael Yee - Jefferies Michael Yee All right. Good morning, everyone.

Amgen Inc. (AMGN) Management Presents at 2022 Jefferies Global Healthcare Conference (Transcript)

Agree Realty

British American Tobacco

Mondelez

Altria

Newell Brands

Reinsurance Group of America

Molson Coors Brewing

Without a doubt, 2022 has been one of the worst years for stock investors in some time.

Why 8 Big-Dividend Defensive Stocks Can Be Huge Winners If Market Struggles Continue

Dow Jones' Best and Worst-Performing Stocks of Today

New Indication for Amgen's Fifth FDA-approved Biosimilar Now Approved to Treat All Available Rituxan® Indications THOUSAND OAKS, Calif. , June 6, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS

First Prospective Study of Treatment in Patients with Wild-Type RAS Colorectal Cancer and Left-Sided Primary Tumor Results From the Phase 3 PARADIGM Trial Being Featured During ASCO 2022 Plenary Session THOUSAND OAKS, Calif. and OSAKA, Japan , June 5, 2022  /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Takeda Pharmaceutical Company (TSE: 4502) today announced that new data from the Phase 3 PARADIGM clinical trial of Vectibix® (panitumumab) in Japanese patients with previously untreated unresectable wild-type RAS metastatic colorectal cancer (mCRC) are being featured during the June 5 Plenary Session (Abstract #LBA1) of the American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago and online.

NEW HEAD-TO-HEAD DATA SHOW VECTIBIX® (PANITUMUMAB) DEMONSTRATED SUPERIOR OVERALL SURVIVAL COMPARED TO BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN JAPANESE PATIENTS WITH WILD-TYPE RAS COLORECTAL CANCER

THOUSAND OAKS, Calif. , June 3, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2022 Jefferies Healthcare Conference at 9:30 a.m.

AMGEN ANNOUNCES WEBCAST OF 2022 JEFFERIES HEALTHCARE CONFERENCE

Lowe's

The market could be on the verge of going a lot higher. Many high-quality stocks are still trading at bargain prices.

Biggest Opportunity Of The Year: 3 High Growth Dividend Stocks To Buy Now

It's never too early to plan for the golden years, and if you started late you can still take advantage of opportunities.

3 of the Best Ways to Invest for Retirement

Amgen's (AMGN) olpasiran, a small interfering RNA molecule, is designed in such a way that it lowers the body's production of apolipoprotein(a), a key component of Lp(a) which increases the risk of cardiovascular events.

Amgen (AMGN) Olpasiran Lowers Lipoprotein Levels in Phase II

Blue-chip name Amgen, Inc.  (NASDAQ:AMGN) earlier reported its olpasiran therapy helped reduce cholesterol levels in patients with atherosclerotic cardiovascular disease (ASCVD), according to topline data from its phase 2 trial.

Blue-Chip Stock Could Soon Cool from Recent Rally

Study Showed Significant, Sustained Reduction in Lipoprotein(a) During Treatment Period Lipoprotein(a) Reduction was Consistent With Phase 1 Results  THOUSAND OAKS, Calif. , May 31, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive topline data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran (formerly AMG 890) in 281 adult patients with Lipoprotein(a), or Lp(a), levels over 150 nmol/L and evidence of atherosclerotic cardiovascular disease (ASCVD).

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a)

Biogen

Moderna

Pfizer

Could these biotech stocks be worth watching in the stock market today?

What Stocks To Invest In Now? 4 Biotech Stocks To Know

New York, New York--(Newsfile Corp. - May 28, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Amgen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class...

Shareholder Alert: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Amgen Inc. - AMGN

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?

Amgen (AMGN) Up 6.3% Since Last Earnings Report: Can It Continue?

Amgen's 3.1% dividend yield is nearly double the S&P 500's -- and that's not the only thing to like about the stock.

News for Amgen Stock (AMGN)